Elsevier

Thrombosis Research

Volume 123, Issue 2, December 2008, Pages 288-297
Thrombosis Research

Regular Article
Thrombin regulates vascular smooth muscle cell proteoglycan synthesis via PAR-1 and multiple downstream signalling pathways

https://doi.org/10.1016/j.thromres.2008.04.019Get rights and content

Abstract

Introduction

Atherosclerosis is the underlying pathological process of most cardiovascular disease. Thrombin is a serine protease which can activate protease activated receptors (PAR) on vascular smooth muscle cells (VSMC) to elicit cellular responses that can contribute to the pathogenesis of atherosclerosis. Human atherosclerosis commences with the binding and retention of lipoproteins by the glycosaminoglycan (GAG) chains of chondroitin/dermatan sulfate proteoglycans. The potential effects of thrombin on the synthesis and structure of CS/DS proteoglycans produced by VSMCs was investigated.

Materials and methods

VSMCs were derived from human internal mammary arteries. Proteoglycan synthesis was assessed by [35S]sulfate and [3H]glucosamine incorporation. Proteoglycan size was assessed by SDS-PAGE and size exclusion chromatography.

Results and conclusion

Thrombin caused a dose-dependent increase in [35S]sulfate and [3H]glucosamine incorporation with maximum effects of approximately 150% at the highest doses tested. This increase was associated with increased size of biglycan and decorin assessed by SDS-PAGE. Chemically cleaved glycosaminoglycan (GAG) chains analyzed by SDS-PAGE and size exclusion chromatography were larger for proteoglycans from thrombin treated cells. VSMCs synthesize small GAGs when provided with exogenous xyloside and thrombin treatment also increased the size of the secreted xyloside GAGs. The effect of thrombin was not mimicked by the catalytically inactive FPRCK-HCT and was blocked in a concentration- dependent manner by the PAR-1 antagonist, JNJ5177049. Inhibition of PK C with GF 109203X resulted in concentration dependent but partial inhibition of [35S]sulfate incorporation accompanied by a reduction in the size of biglycan and decorin. Epidermal growth factor (EGF) stimulated [35S]sulfate incorporation and increased proteoglycan size and this was completely blocked by the EGF receptor tyrosine kinase inhibitor AG1478. AG1478 partially (32%, p < 0.01) blocked the effect of thrombin. Thrombin treatment of VSMCs increased the proportion of disaccharides sulfated at the 6 position of the GalNAc residues. Thus, thrombin has actions on VSMCs which increase the length and modify the sulfation pattern of GAG chains on proteoglycans in a manner that would enhance the binding of LDL. If manifest in vivo, this effect on proteoglycan synthesis and structure represents a new biochemical mechanism through which thrombin contributes to the development of atherosclerosis.

Introduction

Thrombin is a serine protease that is generated by cleavage of its inactive precursor, prothrombin, and has been intensively studied due to its essential role in hemostasis [1]. In the coagulation cascade, thrombin converts the monomer fibrinogen to insoluble fibrin, in addition to activating other clotting factors V, VIII and XIII, thus facilitating thrombus formation. The discovery of seven transmembrane G protein coupled receptors 7TM GPCR, that are activated by proteolytic cleavage [2], demonstrated that thrombin is able to regulate vascular smooth muscle cell (VSMC)s independent of its effects on hemostasis. VSMCs predominantly express protease activated receptor 1 (PAR-1) and PAR-4 [3], although certain VSMC types have been shown to express other PARs [4]. G protein pathways coupled to the PAR-1 receptor include the Gαq/11 regulated phospholipase Cβ/DAG/IP3 pathway [5], the Gα12/13 guanine exchange factor regulated Rho/Rho kinase pathway [6] and Gαi/o mediated pathways [7]. Activation of PAR-1 by thrombin causes cellular effects associated with activation of these pathways, including calcium signalling, proliferation [8], [9], cytoskeletal rearrangement, contraction [10] and extracellular matrix synthesis [11].

Proteoglycans are macromolecules that are composed of a core protein to which sulfated glycosaminoglycan (GAG) chains are covalently attached [12]. These molecules form part of the extracellular matrix of a blood vessel where they play a role in physiological regulation, but also participate in pathological processes including the development of atherosclerotic plaques [13]. Their major role in plaque development occurs very early through binding and retention of lipoproteins in the neointima [13], [14]. Nakashima et al. recently demonstrated that accumulation of lipid in the outer layer of the diffuse intimal thickening of human coronary arteries is the earliest step in the formation of an atherosclerotic lesion. This lipid retention is very closely associated with expression of the proteoglycan, biglycan [14]. Furthermore, O'Brien and colleagues have very recently shown that the accelerated atherosclerosis of diabetes is associated with the enhanced expression of GAGs and proteoglycans [15].

The synthesis and hence structure of the GAG chains on proteoglycans is able to be modified by extracellular mediators. Angiotensin II and transforming growth factor β (TGFβ) both stimulate the synthesis of proteoglycans that have longer GAG chains, a property which causes enhanced proteoglycan binding to LDL [16], [17]. Both agonists stimulate an increase in the expression of chondroitin sulfate (CS) containing proteoglycans, versican and biglycan [18], [19], [20], which has implications for atherogenesis as CS proteoglycans bind LDL with high affinity, whereas heparan sulfate proteoglycans do not demonstrate binding to LDL [21].

Thrombin stimulates the synthesis of proteoglycans from VSMC, particularly, the synthesis of a large heparan sulfate containing proteoglycan, identified as perlecan [22], however nothing is currently known about the effect of thrombin on CS/DS proteoglycans, or the signalling pathways used by thrombin to mediate its effects on proteoglycans. We have investigated the effect of thrombin on the synthesis and structure of CS/DS proteoglycans versican, biglycan and decorin, from human VSMC, and have determined the signalling pathways and mechanisms by which thrombin is able to mediate its effects on the synthesis and structure of proteoglycans.

Section snippets

Materials

Chemicals and reagents were purchased from suppliers as follows: endothelin-1, thrombin, EGF, AG1478, 6-amino caproic acid, benzamidine hydrochloride, methyl-β-D-xylopyranoside (xyloside), DEAE-Sephacel, Sepharose CL-6B, proteinase K, sodium borohydride, chondroitin sulfate and GF109203X (Sigma, St Louis, MO, USA); forskolin (EMD Biosciences, Darmstadt, Germany). Catalytically inactive thrombin (human α thrombin-phenylalanine-proline-arginine-chloromethylketone) (Haemtech, Essex Junction VT,

Thrombin stimulates an increase in the synthesis and size of CS/DS proteoglycans secreted by human VSMC

Quiescent human VSMC were treated with thrombin (0 – 10 or 30 U/mL) for 6 hours prior to addition of either [35S]sulfate (25 μCi/mL) or [3H]glucosamine (20 μCi/ml) for a further 18 hours. Thrombin stimulated a concentration dependent increase in [35S]-sulfate incorporation into secreted proteoglycans (Fig. 1) causing a 190% increase (p < 0.01) at the maximal concentration used (10 U/mL). As an alternative measure of proteoglycan synthesis we assessed the incorporation of [3H]glucosamine into

Discussion

The pro-coagulant serine protease, thrombin, is implicated in the vascular biology of atherosclerosis due to effects on VSMC proliferation and migration and also potentially via effects on secretion of matrix molecules [33]. Proteoglycans have recently been strongly implicated in atherosclerosis but the effect of thrombin on the synthesis and structure of the lipid binding CS/DS proteoglycans synthesized and secreted by VSMCs is unknown. We report that thrombin stimulation of VSMC caused an

Conclusion

The crucial role of proteoglycans in the initiation of atherosclerosis has been supported by extensive data over the last decade and most recently by definitive studies in human pathology [14], [15]. Multiple vasoactive agonists have been identified which regulate GAG synthesis consistent with increasing the atherogenicity of the proteoglycans. In terms of therapeutics it is unlikely that the enzymes or processes of GAG elongation would be suitable targets because these would most likely have

Acknowledgements

This work was supported by the Diabetes Australia Research Trust grants (PJL) and a GlaxoSmithKline Australia post-graduate student award to PJL to support the work of MEI.

References (47)

  • S.V. Subramanian et al.

    Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation

    J Biol Chem

    (1997)
  • P.E. Poleni et al.

    Agonists of peroxisome proliferators-activated receptors (PPAR) alpha, beta/delta or gamma reduce transforming growth factor (TGF)-beta-induced proteoglycans' production in chondrocytes

    Osteoarthritis Cartilage

    (2007)
  • Y. Kanda et al.

    Thrombin activates p38 mitogen-activated protein kinase in vascular smooth muscle cells

    Life Sci

    (2001)
  • H. Ungefroren et al.

    Transforming growth factor-beta (TGF-beta) type I receptor/ALK5-dependent activation of the GADD45beta gene mediates the induction of biglycan expression by TGF-beta

    J Biol Chem

    (2005)
  • H. Dadlani et al.

    Smad and p38 MAP kinase mediated signalling of proteoglycan synthesis in vascular smooth muscle

    J Biol Chem

    (2008)
  • S.R. Coughlin

    Thrombin signalling and protease-activated receptors

    Nature

    (2000)
  • E. Bretschneider et al.

    Evidence for functionally active protease-activated receptor-4 (PAR-4) in human vascular smooth muscle cells

    Br J Pharmacol

    (2001)
  • E. Bretschneider et al.

    Evidence for functionally active protease-activated receptor-3 (PAR-3) in human vascular smooth muscle cells

    Thromb Haemost

    (2003)
  • T.M. Seasholtz et al.

    Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration

    Circ Res

    (1999)
  • M.A. Ayoub et al.

    Real-time analysis of agonist-induced activation of protease-activated receptor 1/Galphai1 protein complex measured by bioluminescence resonance energy transfer in living cells

    Mol Pharmacol

    (2007)
  • P. Andrade-Gordon et al.

    Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor

    Proc Natl Acad Sci U S A

    (1999)
  • B.P. Damiano et al.

    RWJ-58259: a selective antagonist of protease activated receptor-1

    Cardiovasc Drug Rev

    (2003)
  • W.J. Janssens et al.

    Effect of thrombin on isolated canine blood vessels

    Blood Vessels

    (1982)
  • Cited by (45)

    View all citing articles on Scopus
    View full text